press release
Nagi Bioscience makes a strong debut at BIO International as part of the Innosuisse cohort for the Swiss Pavilion
May 30th, 2024
Saint-Sulpice, Switzerland
Nagi Bioscience, a leading Swiss life sciences company developing next-generation laboratory equipment to unlock the full potential of alternatives to animal testing, is proud to announce its debut at BIO International. As part of the selected Innosuisse cohort, Nagi Bioscience will join the prestigious Swiss Pavilion with the aim of establishing strategic collaborations, partnerships, and set foot in the US market. This recognition highlights Nagi’s continuous contributions to accelerate biological testing in an ethical and efficient manner, and its commitment to revolutionizing drug discovery and toxicology testing standards.
Nagi Bioscience has achieved remarkable success since its establishment, accounting for more than thirty publications featuring their patented Organism-on-Chip technology for fundamental research, drug discovery and toxicology. Within the last year, the company earned the Innosuisse Certificate accrediting for sustainable growth, demonstrating exceptional potential for commercial and business scale-up. Their first commercial product, SydLab™ One, constitutes the first end-to-end automated high-content screening platform for drugs, chemicals, and other substances on C. elegans nematodes. The platform, powered by Nagi’s patented Organism-on-Chip technology, attracted significant investor interest due to its capabilities to accelerate and de-risk drug discovery and diseases’ research, resulting in an oversubscribed Series A funding round of 12.4M CHF at the end of 2023.
Since its launch last year, SydLab™ One has gained significant traction across various industries, including pharmaceutical, biotechnology, nutraceuticals, and agrochemical companies, and its already delivering tangible results accelerating the discovery pipelines of a growing base of satisfied customers. Since then, Nagi Bioscience has presented at many prestigious conferences more than fifteen novel scientific datasets produced by the platform in diverse research areas, including the recent publication of a collaborative paper between EPFL and Amsterdam UMC featuring SydLab™ One.
BIO International debut marks expansion goals
This year Nagi Bioscience makes its BIO International debut, the premier global bioindustry event, with the goal of building strategic partnerships to accelerate growth and market reach, expanding collaborative opportunities with key industry players, and showcasing the power and versatility of SydLab™ One. Furthermore, Nagi Bioscience views BIO International as a valuable platform to establish a foothold into the US market, a key next step for the company’s expansion plans.
Meet Nagi Bioscience at BIO International 2024 in San Diego
Nagi Bioscience’s CEO and co-founder, Matteo Cornaglia, along with the recently appointed CCO Regis Duval, will be present at the Swiss Pavilion during the event in San Diego. They are eager to connect with potential partners, customers, and industry professionals to showcase how Nagi’s Organism-on-Chip technology is poised to revolutionize drug discovery and toxicology testing standards, effectively bridging the gap between in vitro and in vivo data.
About Nagi Bioscience
Founded in 2019, Nagi Bioscience is a spin-off of the École Polytechnique Fédérale de Lausanne (EPFL) pioneering the next-generation biological testing landscape for the past 10 years. With its innovative Organism-on-Chip technology, Nagi aims to revolutionize the way new substances are tested today through cutting-edge laboratory equipment that allows to unlock the full potential of small organisms. Under the motto in vivo testing at the in vitro scale, Nagi’s technologies are accelerating drug development pipelines and introducing new toxicology testing standards revolutionizing pharmaceutical, biotech, nutraceutical, cosmetic, and agro-chemical industries with fast, scalable, efficient, and ethical methods. The successful closure of its Series A funding round reflects Nagi’s potential to drive transformative change within the sector of alternatives to animal testing.
For more information, visit www.nagibio.ch
About SydLab™ One
SydLab™ One is the first all-in-one laboratory technology for fully automated high-content screening on small organisms (C. elegans nematodes) to speed-up and de-risk your research and discovery efforts.
Based on Nagi’s patented Organism-on-Chip technology, SydLab™ One combines advanced microfluidic technology with cutting-edge robotics, AI, optics, and biology to automate the entire process of culture, treatment, imaging, and AI multi-phenotypic analysis of C. elegans within a single benchtop laboratory device.
For media inquiries, please contact:
